BR112013007145A2 - composto ou sal farmacologicamente aceitável, medicamento, e, uso do composto ou sal farmacologicamente aceitável - Google Patents
composto ou sal farmacologicamente aceitável, medicamento, e, uso do composto ou sal farmacologicamente aceitávelInfo
- Publication number
- BR112013007145A2 BR112013007145A2 BR112013007145A BR112013007145A BR112013007145A2 BR 112013007145 A2 BR112013007145 A2 BR 112013007145A2 BR 112013007145 A BR112013007145 A BR 112013007145A BR 112013007145 A BR112013007145 A BR 112013007145A BR 112013007145 A2 BR112013007145 A2 BR 112013007145A2
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- pharmacologically acceptable
- group
- acceptable compound
- alkyl group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
composto ou sal farmacologicamente aceitável, medicamento, e, uso do composto ou sal farmacologicamente aceitável. para descobrir um agente terapêutico e/ou profilático para distúrbios gastrointestinais e similares, o agente tendo atividade excelente e segurança elevada. um composto representado pela seguinte fórmula geral (i) ou um sal farmacologicamente aceitável do mesmo. na fórmula, a representa um grupo fenileno opcionalmente substituído; b representa um grupo heterocíclico opcionalmente substituído de 4 e 10 membros, um grupo c6-c10 arila opcionalmente substituído, ou um grupo c3-c10 cicloalquila opcionalmente substituído; r^ 1^ representa um átomo de hidrogênio ou um grupo c-1-c3 alquila; r^ 2^ representa um átomo de hidrogênio ou um grupo c1-c3 alquila; r^ 3^ representa um grupo c1-c6 alquila, um grupo c3-c10 cicloalquila, um grupo c1-c3 alcóxi c1-c3 alquila, ou um grupo c1-c3 hidroxialquila; r^ 4^ representa um átomo de hidrogênio, um grupo c1-c6 alquila, ou um átomo de halogênio; n representa um número inteiro de 1 a 4; e x representa metileno, -o-, -nh-, -n(c1-c3 alquila)-, -c(=o)-, -s(o)-, -s(o~ 2~)-, ou uma ligação única.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010215403 | 2010-09-27 | ||
PCT/JP2011/071830 WO2012043445A1 (ja) | 2010-09-27 | 2011-09-26 | シクロヘキサン誘導体化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013007145A2 true BR112013007145A2 (pt) | 2016-06-14 |
Family
ID=45892891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013007145A BR112013007145A2 (pt) | 2010-09-27 | 2011-09-26 | composto ou sal farmacologicamente aceitável, medicamento, e, uso do composto ou sal farmacologicamente aceitável |
Country Status (29)
Country | Link |
---|---|
US (3) | US8710060B2 (pt) |
EP (1) | EP2623492B1 (pt) |
JP (1) | JP5753179B2 (pt) |
KR (1) | KR20130109124A (pt) |
CN (1) | CN103108866B (pt) |
AU (1) | AU2011309212B2 (pt) |
BR (1) | BR112013007145A2 (pt) |
CA (1) | CA2812898C (pt) |
CO (1) | CO6690804A2 (pt) |
CY (1) | CY1115450T1 (pt) |
DK (1) | DK2623492T3 (pt) |
ES (1) | ES2478518T3 (pt) |
HK (1) | HK1185081A1 (pt) |
HR (1) | HRP20140720T1 (pt) |
IL (1) | IL225440A (pt) |
IN (1) | IN2013MN00506A (pt) |
MX (1) | MX2013003219A (pt) |
MY (1) | MY157542A (pt) |
NZ (1) | NZ609596A (pt) |
PL (1) | PL2623492T3 (pt) |
PT (1) | PT2623492E (pt) |
RS (1) | RS53447B (pt) |
RU (1) | RU2013119603A (pt) |
SG (1) | SG188415A1 (pt) |
SI (1) | SI2623492T1 (pt) |
SM (1) | SMT201400109B (pt) |
TW (1) | TWI501953B (pt) |
WO (1) | WO2012043445A1 (pt) |
ZA (1) | ZA201301652B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2013003219A (es) * | 2010-09-27 | 2013-06-18 | Daiichi Sankyo Co Ltd | Compuesto derivado de ciclohexano. |
US11318350B2 (en) | 2016-12-29 | 2022-05-03 | BioMech Sensor LLC | Systems and methods for real-time data quantification, acquisition, analysis, and feedback |
US10973439B2 (en) | 2016-12-29 | 2021-04-13 | BioMech Sensor LLC | Systems and methods for real-time data quantification, acquisition, analysis, and feedback |
US9773330B1 (en) | 2016-12-29 | 2017-09-26 | BioMech Sensor LLC | Systems and methods for real-time data quantification, acquisition, analysis, and feedback |
US10352962B2 (en) | 2016-12-29 | 2019-07-16 | BioMech Sensor LLC | Systems and methods for real-time data quantification, acquisition, analysis and feedback |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511980B2 (en) * | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
US7262195B2 (en) * | 2003-09-17 | 2007-08-28 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
GB0611907D0 (en) | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
GB0515381D0 (en) * | 2005-07-26 | 2005-08-31 | Glaxo Group Ltd | Compounds |
JP5028484B2 (ja) * | 2006-06-28 | 2012-09-19 | グラクソ グループ リミテッド | Gpr38受容体媒介疾患の治療に有用なピペラジニル誘導体 |
GB0612844D0 (en) * | 2006-06-28 | 2006-08-09 | Glaxo Group Ltd | Compounds |
GB0723317D0 (en) | 2007-11-28 | 2008-01-09 | Glaxo Group Ltd | Compounds |
MX2013003219A (es) * | 2010-09-27 | 2013-06-18 | Daiichi Sankyo Co Ltd | Compuesto derivado de ciclohexano. |
-
2011
- 2011-09-26 MX MX2013003219A patent/MX2013003219A/es active IP Right Grant
- 2011-09-26 PL PL11828999T patent/PL2623492T3/pl unknown
- 2011-09-26 ES ES11828999.0T patent/ES2478518T3/es active Active
- 2011-09-26 BR BR112013007145A patent/BR112013007145A2/pt not_active IP Right Cessation
- 2011-09-26 WO PCT/JP2011/071830 patent/WO2012043445A1/ja active Application Filing
- 2011-09-26 RS RS20140388A patent/RS53447B/en unknown
- 2011-09-26 KR KR1020137007448A patent/KR20130109124A/ko not_active Application Discontinuation
- 2011-09-26 IN IN506MUN2013 patent/IN2013MN00506A/en unknown
- 2011-09-26 NZ NZ609596A patent/NZ609596A/en not_active IP Right Cessation
- 2011-09-26 SI SI201130160T patent/SI2623492T1/sl unknown
- 2011-09-26 CN CN201180046082.8A patent/CN103108866B/zh not_active Expired - Fee Related
- 2011-09-26 SG SG2013016464A patent/SG188415A1/en unknown
- 2011-09-26 JP JP2012536427A patent/JP5753179B2/ja not_active Expired - Fee Related
- 2011-09-26 TW TW100134525A patent/TWI501953B/zh not_active IP Right Cessation
- 2011-09-26 EP EP11828999.0A patent/EP2623492B1/en active Active
- 2011-09-26 MY MYPI2013000841A patent/MY157542A/en unknown
- 2011-09-26 RU RU2013119603/04A patent/RU2013119603A/ru not_active Application Discontinuation
- 2011-09-26 CA CA2812898A patent/CA2812898C/en not_active Expired - Fee Related
- 2011-09-26 AU AU2011309212A patent/AU2011309212B2/en not_active Ceased
- 2011-09-26 PT PT118289990T patent/PT2623492E/pt unknown
- 2011-09-26 DK DK11828999.0T patent/DK2623492T3/da active
-
2013
- 2013-03-04 ZA ZA2013/01652A patent/ZA201301652B/en unknown
- 2013-03-21 IL IL225440A patent/IL225440A/en not_active IP Right Cessation
- 2013-03-26 US US13/850,981 patent/US8710060B2/en active Active
- 2013-04-19 CO CO13101069A patent/CO6690804A2/es active IP Right Grant
- 2013-11-11 HK HK13112618.2A patent/HK1185081A1/xx not_active IP Right Cessation
- 2013-12-27 US US14/142,479 patent/US9051255B2/en not_active Expired - Fee Related
- 2013-12-27 US US14/142,486 patent/US20140221392A1/en not_active Abandoned
-
2014
- 2014-07-25 HR HRP20140720AT patent/HRP20140720T1/hr unknown
- 2014-08-06 CY CY20141100614T patent/CY1115450T1/el unknown
- 2014-08-06 SM SM201400109T patent/SMT201400109B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
CO6341631A2 (es) | Derivados de 1,2,4 - oxadiazol y su uso terapéutico | |
EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
EA201100037A1 (ru) | Органические соединения | |
BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
CL2012001072A1 (es) | Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas. | |
BRPI0809656B8 (pt) | atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica | |
MX2014003043A (es) | Formas solidas de un inhibidor de disociacion transtiretina. | |
MX2010006202A (es) | Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
BR112013007145A2 (pt) | composto ou sal farmacologicamente aceitável, medicamento, e, uso do composto ou sal farmacologicamente aceitável | |
EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
AR080172A1 (es) | (r) -4- ((4-((4-(tetrahidrofuran-3-iloxi) benzo (d) isoxazol-3-iloxi)metil)piperidin-1-il)metil) tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4 y composiciones farmaceuticas que los comprenden | |
UY33150A (es) | Compuestos carboxamida y su uso como inhibidores v de calpaína | |
AR089297A1 (es) | Uso de derivados de diamida antranilicos con sustituyentes heteroaromaticos y heterociclicos en combinacion con un agente de control biologico | |
AR091773A1 (es) | Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso | |
MY157425A (en) | Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |